CAMK2N1 inhibits prostate cancer progression through androgen receptor-dependent signalingTao Wang, Ke Chen, Shuiming Guo et al.|Oncotarget|2014Cited by 67
The tumor suppressive role of CAMK2N1 in castration-resistant prostate cancerTao Wang, Kexin Chen, Zhuo Liu et al.|Oncotarget|2014Cited by 44
Tislelizumab in combination with gemcitabine plus cisplatin chemotherapy as first-line adjuvant treatment for locally advanced or metastatic bladder cancer: a retrospective studyXiang Ren, Yiqun Tian, Zhixian Wang et al.|BMC Urology|2022Cited by 23
Preserved Erectile Function in the Aged Transgenic Rat Harboring Human Tissue Kallikrein 1Yang Luan, Dao Wen Wang, Yajun Ruan et al.|The Journal of Sexual Medicine|2016Cited by 15
Tislelizumab in combination with gemcitabine plus cisplatin chemotherapy as first-line adjuvant treatment for locally advanced or metastatic bladder cancer: a retrospective studyXiang Ren, Yisheng Yin, Ruibao Chen et al.|Research Square|2022Cited by 4